secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mosaic ImmunoEngineering Inc. (CPMV)
CIK:        0000836564
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001683168-22-003217
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mosaic ImmunoEngineering secures exclusive worldwide CPMV license from Case Western Reserve University
--------------------------------------------------------------------------------

- Licensed technology covers cowpea mosaic virus (CPMV)-based oncology treatments for human and companion animal cancers.
- Development milestone payments up to $1.8M per human product; tiered royalties starting in mid-single digits on net sales.
- Annual minimum royalty of $10,000 starting year 2, rising based on net sales; CWRU to be reimbursed ~$278K in IP fees.
- Agreement term runs 20 years or last patent expiry; Mosaic gains rights to core technology behind lead candidate MIE-101.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/836564/000168316822003217/0001683168-22-003217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/836564/000168316822003217/mosiac_8k-050422.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-003217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer